BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 28, 2007
View Archived Issues
Neurochem Slides 43 Percent On Alzhemed Phase III Failure
After six months of number crunching, Neurochem Inc. confirmed what most analysts already suspected: the North American Phase III trial of Alzhemed (tramiprosate) in Alzheimer's disease did not meet its primary endpoints. (BioWorld Today)
Read More
FDA Sends IDM's Junovan Back For More Trial Data
Read More
Stem Cell Transplants Give Hope For Bedside, Lessons For Bench
Read More
BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury
Read More
Upstream Completes Acquisition Of Firm Focused On Parasites
Read More
Financings Roundup
Read More
Other News To Note
Read More
Clinic Roundup
Read More
